Stocks and Investing
Stocks and Investing
Tue, February 20, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sumant Kulkarni Maintained (BIIB) at Strong Buy with Decreased Target to $305 on, Feb 20th, 2024
Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $310 to $305 on, Feb 20th, 2024.
Sumant has made no other calls on BIIB in the last 4 months.
There are 13 other peers that have a rating on BIIB. Out of the 13 peers that are also analyzing BIIB, 3 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Colin Bristow of "UBS" Maintained at Hold with Decreased Target to $250 on, Friday, February 16th, 2024
- Mohit Bansal of "Wells Fargo" Downgraded from Buy to Hold and Decreased Target to $240 on, Wednesday, February 14th, 2024
- Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $239 on, Thursday, November 9th, 2023
These are the ratings of the 10 analyists that currently disagree with Sumant
- Evan Seigerman of "BMO Capital" Maintained at Buy with Decreased Target to $285 on, Wednesday, February 14th, 2024
- Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $290 on, Wednesday, February 14th, 2024
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $300 on, Wednesday, February 14th, 2024
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $325 on, Wednesday, February 14th, 2024
- Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $364 on, Wednesday, February 14th, 2024
- Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $316 on, Wednesday, February 14th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $325 on, Wednesday, February 14th, 2024
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $287 on, Thursday, December 14th, 2023
- Danielle Brill of "Raymond James" Upgraded from Hold to Buy and Held Target at $283 on, Thursday, December 7th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $373 on, Friday, November 10th, 2023
Contributing Sources